Latest news
Q2 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocusGuruFocus · Sat, 08 Aug 2026 12:29:57 GMTTRVI Maintains Overweight Rating -- Price Target Raised to $30 b - GuruFocusGuruFocus · Fri, 07 Aug 2026 14:43:07 GMTTRVI SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocusGuruFocus · Fri, 07 Aug 2026 10:33:06 GMTTrevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ... - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 05:08:55 GMTTrevi Therapeutics (TRVI) Advances Clinical Trials Amid High Val - GuruFocusGuruFocus · Fri, 07 Aug 2026 00:32:13 GMT